百时美施贵宝

Bristol-Myers Squibb's 15min chart signals Bollinger Bands Narrowing, KDJ Death Cross detected.

Bristol-Myers Squibb: Scotiabank maintains Sector Perform, PT raised to $53 from $45.

Bristol-Myers Squibb's 15min Chart Shows MACD, KDJ Death Crosses

Bristol-Myers Squibb's 15min chart triggers MACD Golden Cross, Bollinger Bands expanding upward.

Catalyst<ul> <li>Positive net inflows from small and extra-large institutional orders indicate accumulating support for BMY.</li></ul>Risk<ul> <li>Analyst ratings are all Neutral, showing limited optimism and highlighting uncertain market expectations for BMY.</li> <li>Technical indicators show a bearish bias with no clear trend, increasing the risk of continued price volatility for BMY.</li></ul>

Key Factors

Bristol Myers Squibb announces continuation of ADEPT-2 Phase 3 trial for Alzheimer’s-related psychosis and expands patient enrollment to address site execution issues.Bristol-Myers Squibb faces a $6.7 billion lawsuit alleging delayed drug approvals to avoid Celgene shareholder payments.Scotiabank raises price target for Bristol-Myers Squibb to $53 from $45 and maintains Sector Perform rating.

BMY News